As it races to complete and make public the raw human genome sequence, Celera Genomics Corp. recently has taken back-of-the-hand shots from academic competitors and their sympathizers in the White House and 10 Downing Street. But the real question is how CRA will add value to its databases long after the hullabaloo over the publicly available raw sequence dies down.

Thus the company's acquisition of bioinformatics company Paracel Inc. last week provides a more useful insight into CRA's strategy, which is to assemble a comprehensive biological information portfolio using complementary genomics, proteomics and genetic analysis technologies.